2017
Update - July 2017
Opportunities for Fab'entech in 2017
Opportunities for Fab'entech in 2017
2015
Orphan drug designation - June 2015
Fab'entech has been granted with orphan medicinal product designation from the European Medicines Agency for Fabenflu®, its avian influenza (H5N1) product
GMP compliance - May 2015
Fab'entech has been granted with a certificate of GMP compliance by French National Agency for Medicines and Health Products Safety
Ebola program - February 2015
Fab'entech has started the development of an immunotherapy candidate targeting Ebola infections
Fab'entech has been granted with orphan medicinal product designation from the European Medicines Agency for Fabenflu®, its avian influenza (H5N1) product
GMP compliance - May 2015
Fab'entech has been granted with a certificate of GMP compliance by French National Agency for Medicines and Health Products Safety
Ebola program - February 2015
Fab'entech has started the development of an immunotherapy candidate targeting Ebola infections
2014
Fundraising - June 2014
Fab'entech has completed a 5 M€ fundraising
Fab'entech has completed a 5 M€ fundraising
2012
Clinical trial - October 2012
Fab'entech has started a phase I clinical trial for its immunotherapy candidate targeting avian influenza (H5N1)
Grant program - February 2012
Fab'entech has been awarded with a grant of 7.1 M€ for its participation in the EMER-IT project
Fab'entech has started a phase I clinical trial for its immunotherapy candidate targeting avian influenza (H5N1)
Grant program - February 2012
Fab'entech has been awarded with a grant of 7.1 M€ for its participation in the EMER-IT project
